Pembrolizumab approved in US for first line use in locally advanced or metastatic oesophageal or gastroesophageal junction carcinomas regardless of PD-L1 expression

Approval was based on data from the Phase III KEYNOTE-590 trial of 749 patients which found the combination of pembrolizumab with fluorouracil and cisplatin reduced the risk of death by 27% as compared to cisplatin alone.

Source:

Biospace Inc.